Actively Recruiting
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Led by CellCentric Ltd. · Updated on 2026-04-22
100
Participants Needed
11
Research Sites
201 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.
CONDITIONS
Official Title
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female 18 years of age or older
- Diagnosed with multiple myeloma relapsed or refractory to last therapy
- ECOG performance status of 0 to 2
- Adequate blood, kidney, and liver function
- Willing to use effective contraception if sexually active
You will not qualify if you...
- Use of investigational, chemotherapy, immunotherapy, or anticancer agents within 14 days or 5 half-lives before study treatment; antibody therapy within 30 days
- Prior treatment with p300/CBP bromodomain inhibitors
- Known or suspected severe allergies to study drugs or prior immunomodulatory drugs
- Taking medicines, supplements, or foods that interfere with treatment
- Major surgery within 4 weeks before study treatment
- Live vaccine within 4 weeks before study treatment
- Active or unresolved adverse events
- Active or progressing cancers other than multiple myeloma within last 24 months
- Pregnant or breastfeeding women
- Any illness or history affecting safety, compliance, or data interpretation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
Winship Cancer Institute
Atlanta, Georgia, United States, 30322
Actively Recruiting
2
American Oncology Partners, PA
Bethesda, Maryland, United States, 20817
Actively Recruiting
3
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
Actively Recruiting
4
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
5
The Christie NHS Foundation Trust
Withington, Greater Manchester, United Kingdom, M20 4BX
Actively Recruiting
6
Royal Marsden NHS Foundation Trust
Sutton, London, United Kingdom, SM2 5PT
Actively Recruiting
7
The Clatterbridge Cancer Centre NHS Foundation Trust
Bebington, Wirral, United Kingdom, CH63 4JY
Actively Recruiting
8
Western General Hospital
Edinburgh, United Kingdom, EH4 2XU
Actively Recruiting
9
Barts Health NHS Trust
London, United Kingdom, EC1A 7BE
Actively Recruiting
10
King's College Hospital NHS Foundation Trust
London, United Kingdom, SE5 9RS
Actively Recruiting
11
Imperial College Healthcare NHS Trust, Hammersmith Hospital
London, United Kingdom, W12 0HS
Actively Recruiting
Research Team
C
CCS1477-04 Clinical Operations
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here